Evidence map›Paper›PMID 8882642›Full record

ArticleGene expression1996

GAL4-VP16 stimulates two RNA polymerase II promoters primarily at the preinitiation complex assembly step.

G A Jacob, D S Luse

Abstract read
In one paragraph

Article in Gene expression, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

G A JacobDepartment of Molecular Genetics, University of Cincinnati College of Medicine, OH 45267-0522, USA.
D S Luse
University of Cincinnati · US

Funding

CONTROL OF TRANSCRIPTION IN EUKARYOTIC CELLSR01GM029487 · NIGMS · UNIVERSITY OF CINCINNATI · PI LUSE, DONAL · 1985 to 2009
$2.7M
NIGMS NIH HHS GM 29487NIGMS NIH HHS R01 GM029487
6 · The paper itself

Abstract

We previously demonstrated that RNA polymerase II promoters may be limited in strength not only at the step of transcription complex assembly, but also at initiation or promoter clearance. Here we report on experiments designed to test the possibility that steps following transcription complex assembly might be stimulated by transcriptional activators. Using an in vitro system in which we can independently measure the efficiency of assembly, initiation, and promoter clearance, we have investigated the mechanism by which the model activator GAL4-VP16 increases transcription from two promoters: a weak variant of Ad 2 ML with an altered TATA box, which is inefficient in transcription initiation, and the mouse beta-globin promoter, which is inefficient in promoter clearance. We found that whereas GAL4-VP16 is effective in stimulating both promoters, this increase resulted only from greater transcription complex assembly; the initiation and clearance steps were not affected. Because recent studies have suggested that the core transcription factors TFIIE and TFIIH might be important in promoter clearance, we also attempted to increase the initiation and clearance efficiencies of the Ad ML-TATA mutant and globin promoters by direct addition of excess TFIIE and TFIIH to partially purified preinitiation complexes assembled at each of these promoters. These factors had no effect on transcription by either of the preinitiation complexes.

Indexed as

Transcription, GeneticAnimalsFungal ProteinsGlobinsMicePromoter Regions, GeneticRecombinant Fusion ProteinsRNA Polymerase IITrans-ActivatorsFungal ProteinsGal-VP16GlobinsRecombinant Fusion ProteinsRNA Polymerase IITrans-Activators

Identifiers

PMID8882642
PMCPMC6138014
OpenAlexW2396658524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.